Altimmune, Inc. (ALT) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $640M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAltimmune, Inc. (ALT) trades at $3.29 with MoonshotScore 28/100 (Grade F). Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases.
Price as of Sep 11, 2026 · Last analyzed: Sep 9, 2026Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Their lead product candidate, pemvidutide, is in Phase 1b trial for obesity and non-alcoholic steatohepatitis.
ALT stock analysis for 2026: Analysts have set a consensus price target of $6.25 for Altimmune, Inc., suggesting 90.0% upside from the current price of $3.29. The AI MoonshotScore is 28/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
ALT: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Financial Safety (8/10, Moderate). Weakest side: Business Quality (2/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Altimmune, Inc. Company Overview
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 67% of our measures
- ● Price is current
- ● Latest filing 189 days ago
- ● Covered by analysts
Why 28?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.60 Short-term liquidity (Financial Strength)
- +0.19 Volatility vs the market (Financial Strength)
- +0.18 Price to book (Valuation)
What is holding it back
- -0.78 Gross margin (Business Quality)
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
Risk penalties applied
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
How Altimmune, Inc. Is Valued
Altimmune, Inc. carries a market capitalization of $640M, placing it in the small-cap category.
Altimmune, Inc. Financial Trajectory
Altimmune, Inc. (ALT) reported $26K in revenue for Q4 FY2025, reflecting 420.0% growth compared to the prior quarter. The company recorded a net loss of $27.4M, with diluted EPS of $-0.27.
ALT Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $26,000 | -$27M | -$0.27 |
| Q3 FY2025 | $5,000 | -$19M | -$0.21 |
Q4 FY2025 · filed 6 Mar 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
ALT Latest News
No recent news available for ALT.
ALT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ALT.
Price Targets
Consensus target: $6.25
ALT MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ALT scores 28/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Altimmune, Inc. Stock: Key Questions Answered
What does the AI Score mean for ALT?
ALT holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ALT a good stock?
Stock Expert AI does not rate ALT buy, sell or hold. Altimmune, Inc. carries a MoonshotScore of 28/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for ALT?
Altimmune, Inc. (ALT) holds an AI score of 28/100 (low). Analysts target $6.25 (+90%). Not financial advice.
How frequently does ALT data refresh on this page?
ALT's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALT's recent stock price performance?
Altimmune, Inc. (ALT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALT overvalued or undervalued right now?
Altimmune, Inc. (ALT) is loss-making, so its trailing P/E is negative (-2.45x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $6.25 (+90%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ALT?
Yes, most major brokerages offer fractional shares of Altimmune, Inc. (ALT) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALT's earnings and financial reports?
Altimmune, Inc. (ALT) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ALT earnings announcements.
What should investors new to ALT understand first?
Altimmune, Inc. (ALT) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 28/100. With a market cap of $639.82M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.